NCT05499026已完成不适用
Retrospective Cohort Study to Investigate the Safety and Efficacy of Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
Leadiant Biosciences Ltd.0 个研究点目标入组 28 人开始时间: 2014年12月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 主要终点
- Serum Cholestanol Levels
研究概览
简要总结
Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of CTX Received treatment with CDCA Age between 2 and 75 years Having at least one cholestanol level and/or urinary bile alcohol level no more than 3 months prior to treatment with CDCA and one cholestanol level and/or urinary bile alcohol level post-treatment within 2 years from the beginning of therapy with CDCA
排除标准
- 未提供
结局指标
主要结局
Serum Cholestanol Levels
时间窗: 34 years
次要结局
未报告次要终点
研究者
相似试验
Enrolling By Invitation
不适用
Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III StudyIschemic StrokeNCT05598775ReNeuron Limited9
撤回
3 期
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous XanthomatosesNCT06260748Leadiant Biosciences, Inc.10
已完成
不适用
Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia BHemophilia BNCT02971969Ultragenyx Pharmaceutical Inc6
已完成
2 期
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)Chronic Obstructive Pulmonary Disease (COPD)NCT00993707Turino, Gerard, M.D.11
已完成
1 期
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectableTransarterial ChemoembolizationTyrosine Kinase InhibitorImmune Checkpoint BlockadeNCT04997850Xinrui Zhu，MD142